Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
暂无分享,去创建一个
K. Spiekermann | M. Pfreundschuh | L. Kanz | R. Hehlmann | A. Fabarius | A. Neubauer | A. Hochhaus | M. Müller | S. Krause | R Hehlmann | B. Hanfstein | M Pfreundschuh | L Kanz | J Hasford | M C Müller | A Hochhaus | M. Pfreundschuh | J. Hasford | L Kalmanti | S Saussele | M Lauseker | C T Dietz | L Heinrich | B Hanfstein | U Proetel | A Fabarius | S W Krause | S Rinaldetti | J Dengler | C Falge | E Oppliger-Leibundgut | A Burchert | A Neubauer | F Stegelmann | K Spiekermann | C Scheid | M Pfirrmann | S. Saussele | F. Stegelmann | A. Burchert | M. Lauseker | M. Pfirrmann | C. Scheid | C. Dietz | U. Proetel | J. Dengler | C. Falge | L. Kalmanti | S. Rinaldetti | E. Oppliger-Leibundgut | L. Heinrich | J. Hasford | Lothar Kanz | L. Kanz | A. Hochhaus | Susanne Saussele | Andreas Burchert | Rüdiger Hehlmann | M. Müller | Markus Pfirrmann | S. Saussele | Michael Lauseker | Benjamin Hanfstein | K. Spiekermann | Lida Kalmanti | Ulrike Proetel | Frank Stegelmann | Susanne Saußele
[1] I. Flinn,et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. , 2011, The Lancet. Oncology.
[2] Arnon Nagler,et al. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. , 2011, Blood.
[3] M. Breccia,et al. Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors. , 2013, Leukemia research.
[4] H. Kantarjian,et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. , 2006, Blood.
[5] H. Kantarjian,et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors , 2013, American journal of hematology.
[6] J. Hasford,et al. Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase , 2014, Journal of Cancer Research and Clinical Oncology.
[7] Martin C. Müller,et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. , 2010, Blood.
[8] Martin C. Müller,et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Martin C. Müller,et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. , 2008, Blood.
[10] H. Einsele,et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) , 2012, Leukemia.
[11] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[12] Deborah L White,et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. , 2008, Blood.
[13] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[14] J. Radich,et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Hasford,et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. , 2011, Blood.
[16] N. Cross,et al. Harmonization of molecular monitoring of CML therapy in Europe , 2009, Leukemia.
[17] Tillmann Krahnke,et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. , 2008, Blood.
[18] A. Nagler,et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. , 2011, Journal of the National Cancer Institute.
[19] M. Gordon. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .
[20] M. Deininger,et al. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia , 2011, Leukemia.
[21] H. Einsele,et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib , 2014, Leukemia.
[22] Martin C. Müller,et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. , 2011, Blood.
[23] K. Vandyke,et al. Dysregulation of bone remodeling by imatinib mesylate. , 2010, Blood.
[24] R. Hehlmann,et al. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia , 2011, Leukemia.
[25] Stefan W Krause,et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Deininger,et al. Management of drug toxicities in chronic myeloid leukaemia. , 2009, Best practice & research. Clinical haematology.
[27] Philippe Rousselot,et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.
[28] J. Melo,et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. , 2013, Blood.
[29] P. Loehrer. Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate , 2007 .
[30] Susan Branford,et al. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study , 2014, International Journal of Hematology.
[31] Simona Soverini,et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.
[32] F. Giles,et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis , 2013, Leukemia.
[33] H. Kantarjian,et al. Ten-year follow up of patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with 400 mg or 800 mg of imatinib daily. , 2014 .
[34] Susan Branford,et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] J. Burke,et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Susan Branford,et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. , 2013, Blood.
[37] Claude Preudhomme,et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. , 2010, The New England journal of medicine.
[38] M. Gordon. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia , 2010 .
[39] J. Radich,et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2010, Leukemia.
[40] Francisco Cervantes,et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.
[41] J. Radich,et al. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia , 2014, British journal of haematology.
[42] N. Cross,et al. Standardized definitions of molecular response in chronic myeloid leukemia , 2012, Leukemia.
[43] T. Brümmendorf,et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] S. Fitter,et al. Long-term imatinib therapy promotes bone formation in CML patients. , 2008, Blood.
[45] Rishard Salie,et al. Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia. , 2010, Clinical lymphoma, myeloma & leukemia.
[46] B. Dörken,et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib , 2013, Leukemia.
[47] I. Judson,et al. The safety profile of imatinib in CML and GIST: long-term considerations , 2011, Archives of Toxicology.